BidaskClub Downgrades OraSure Technologies (OSUR) to Sell

OraSure Technologies (NASDAQ:OSUR) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Wednesday.

Other research analysts have also recently issued research reports about the company. TheStreet raised OraSure Technologies from a “c+” rating to a “b” rating in a report on Thursday, August 9th. ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday, November 6th. Raymond James reissued a “mkt perform” rating on shares of OraSure Technologies in a research note on Tuesday, October 23rd. Finally, Zacks Investment Research downgraded shares of OraSure Technologies from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. OraSure Technologies presently has an average rating of “Hold” and an average target price of $20.50.

NASDAQ OSUR opened at $12.64 on Wednesday. The firm has a market capitalization of $777.87 million, a price-to-earnings ratio of 24.78, a P/E/G ratio of 3.21 and a beta of 1.55. OraSure Technologies has a 1 year low of $12.27 and a 1 year high of $22.22.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.02. The company had revenue of $45.90 million for the quarter, compared to analysts’ expectations of $44.50 million. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.49%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.09 earnings per share. On average, equities research analysts forecast that OraSure Technologies will post 0.32 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in OraSure Technologies by 5.9% during the 3rd quarter. BlackRock Inc. now owns 8,979,357 shares of the medical instruments supplier’s stock valued at $138,732,000 after purchasing an additional 498,527 shares during the period. Vanguard Group Inc. raised its stake in OraSure Technologies by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 3,576,389 shares of the medical instruments supplier’s stock valued at $55,256,000 after purchasing an additional 53,671 shares during the period. Dimensional Fund Advisors LP raised its stake in OraSure Technologies by 2.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,886,966 shares of the medical instruments supplier’s stock valued at $44,604,000 after purchasing an additional 58,307 shares during the period. Primecap Management Co. CA raised its stake in OraSure Technologies by 15.0% during the 3rd quarter. Primecap Management Co. CA now owns 1,718,000 shares of the medical instruments supplier’s stock valued at $26,543,000 after purchasing an additional 224,000 shares during the period. Finally, Morgan Stanley raised its stake in OraSure Technologies by 352.3% during the 3rd quarter. Morgan Stanley now owns 1,290,002 shares of the medical instruments supplier’s stock valued at $19,930,000 after purchasing an additional 1,004,774 shares during the period. 92.63% of the stock is currently owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Read More: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit